Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (starpan/STAR-02 Study)

C. Pinto, F. Di Fabio, E. Maiello, S. Pini, T. Latiano, C. Aschele, C. Garufi, A. Bochicchio, G. Rosati, G. Aprile, S. Giaquinta, V. Torri, A. Bardelli, M. Gion, A. Martoni

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The aim of this phase II study was to assess the activity of panitumumab in combination with oxaliplatin, 5-fluorouracil, and external radiotherapy (RT) as preoperative treatment in locally advanced rectal cancer patients. Patients and methods: Patients had rectal adenocarcinoma, cT3N+ or cT4N2/+ stage, located

Original languageEnglish
Pages (from-to)2424-2430
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number11
DOIs
Publication statusPublished - Nov 2011

Keywords

  • 5-fluorouracil
  • Chemoradiotherapy
  • Oxaliplatin
  • Panitumumab
  • Radiotherapy
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (starpan/STAR-02 Study)'. Together they form a unique fingerprint.

Cite this